DOCSLIB.ORG

Subject Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subject Index Subject Index A 68930 130 appetitive Conditions 81 A 86929 130 arachidonic acid 185,223 acetylcholine (ACh) 9 arcuate nucleus 89,97 acoustic neurinoma 227 aripiprazole 36 ACTH, see Adrenocortcotropic asynaptic release 100 hormone 173 ATF1, see Activating transcription factor activating transcription factor 1 (ATF 1) 1 326 attention 276 adaptive reponses 321 attention deficit hyperactivity disorder adenosine A2A receptor 164 (ADHD) 278 adenosine triphosphatase 269, 306 autism 128 adenylyl cyclase 11, 121, 163, 185, 236 autoreceptor 34 ADHD, see attention deficit aversive conditions 81 hyperactivity disorder adrenal gland 173 basal ganglia 31,166,310 adrenal medullary hormones 25 bed nucleus 55 adrenocorticotropic hormone (ACTH) benzazepine 130, 140 173 benzonaphtazepine 131 aggression 276 benztropine 270 akinesia 167 beta (~) adrenoreceptor 10, 238 alcohol 33, 169,203 beta (~)-arrestin 135 alpha (a)olf protein 237 beta (~)-endorphin 173 alpha (a)receptor adrenergic 10 biogenic amines 29 alpha's protein 237 bipolar cell 92 alpha-(a) melanocyte stimulating bipolar disorder 127,227 hormone (a-MSH) 171 bradykinesia 167 alpha-(a) methyltyrosine 33 brain development 201 amacrine cells 92 brain-derived neurotrophic factor amineptine 206 (BDNF) 187 aminotetralin 195 bromocriptine 12, 171, 309 amisulpride 196 brown adipose tissue 243 amitriptyline 206 buproprion 206 AMPA receptor channels 333 butaclamol 125,131 amperozide 196 amphetamine 12,33,135, 169,270,276, calbindin (CaBP) 44,87 325 calcineurin 244 amphetamine stereoselectivity 262 calcium channels 302 amygdala 55, 81, 137 calcium chela tors 303 antidepressant drugs 206 calcium-binding protein, see calbindin antipsychotic treatment 199 87 antisense oligonucleotides 143 calmodulin 239 antisense-treatment 277 calretinin 87 apomorphine 12, 35 cAMP-dependent kinase 186 340 Subject Index cAMP-response element binding protein dentate gyrus 52 (CREB) 163,241 desipramine 207,257,264 carpipramine 196 dextran amine, biotinylated 65 Catalase 170 diagonal band nuclei 79 caudate neuron activity 9 dihydrexidine 130,141 caudate nucleus 5,68 beta (B)-3,4-dihydroxyphenylethylamine central (amygdala) nucleus 55 2 cerebellar peduncle, superior 44 3,4-dihydroxyphenylserine (DOPS) 4 c-fos 191, 325 diphenylpiperazine 257 chlorpromazine 24,30,196,223 dopa decarboxylase 2, 23 cholera toxin 133 dopa decarboxylase inhibitors 5 cholezystokinin 189 dopamine axons 67 choline 268 - transmitting elements 96 choline acetyltransferase 73 dopamine de nervation 312 choroid plexus 243 dopamine neurons ultrastructure chromaffin cells 243 63 clathrin 275 dopamine pathway, nigrostriatal 6 clozapine 33,196,223,228,327 dopamine projection gradient 46 cocaine 30,169,197,203,257,325 dopamine receptor activation 301 cocaine antagonists 262, 273 dopamine receptor agonist 34 cognition 43 dopamine receptor antagonist 34 concanavalin A 135 dopamine receptor concept 11 cortex, temporal 85 dopamine signal transduction 238 cortical afferents 78 dopamine transmission 64, 103 cortical areas, sensory 84 dopamine transporter (DAT) 66, 76 cortico-ventrotriatal circuits 199 - topology 259 COS-7 cells 223 - gene 263 CREB, see cAMP-response element - immunoreactivity 266 binding protein - polymorphism 280 Cushing's syndrome 173 - expression 89 cyclic adenosine monophosphate dopamine uptake inhibitors 206, 272, (cAMP) 132,322 275 dopamine varicosities 67 DI (Dopamine!) receptor 12,74,121, dopamine, 321 - vasopressor action DI (dopamine I) receptor - regional distribution 26 - labelling 75 dopamine-beta(~)-hydroxylase (DBH) - distribution 88 66 - molecular cloning 121 dorsal tier 46 - point mutations 124 drug addiction 299 - truncation 125 dynamine 135 Die (dopamined receptor 145 dynorphin 187,204,326 D2 (dopaminez) receptor 12,35,74 - agonists 308 electroconvulsive shocks 207 - knockout 165 emonapride 227 D3 (dopamine3) receptor 78 endocrine tumors 161 - coupling 186 enkephalin 72,169,302,327 - overexpression 194 epileptic seizures 171 D4 (dopamine4) receptor epinephrine 223 - gene 225 ergot alkaloids 12 - labelling 89 ethanol, see alcohol Ds (dopamines) receptor 74 excitatory postsynaptic potential (EPSP) DARPP-32 242 304 DARPP-32 phosphorylation 244 excitatory synaptic input 305 densocellular area 52 exocytosis 30, 100 densocellular group 47 extrapyramidal side effects 34 Subject Index 341 fiber degeneration 54 incerto-hypothalamic system 89 fibroblasts 186 indolophenanthridine 130 fiuoxetine 206 inducible CRE repressor (ICER) forebrain 43 326 forskolin 186 intercalated cell groups 81 interneurons, cortical 87 G protein 101,322 intervaricose segments 70 G protein activation 134 intrinsic membrane conductance 306 G protein coupled receptors (GPCR) inwardly rectifying K+ (IRK) channels 122, 161 303 gamma-(y)aminobutyric acid (GABA) ionic conductance 304 11,68,167,300 ischemia 170 gamma-(y)aminobutyric acid (GABA) A islands of Calleja 187 receptors 304 isochroman 130 gamma-(y)aminobutyric acid (GABA) isoquinoline 131,140 dendrites 86 gene expression 99 lun N-terminal kinase (JNK) 329 glia 87 globus pallidus 79,166 K+ channels 163 glutamate 9,54 kainic acid 171 glutamate receptor 245 Kir2 channels 301 glutamate receptor subunit 2 (Glu R2) 333 lactotroph cells 161 glutamate terminals 72 L-Dopa 5,27,142,174,193 glutamate transmission 82 learning 43,276,309 glutaraldehyde 64 levodopa, see L-Dopa glutathioine 170 light-dark adaptation 92, 99 golgi impregnation subtypes 74 limbic areas, forebrain 6 grooming 139 limbic brain 54, 185 growth hormone-releasing hormone limbic cortex 6 172 lisuride 309 GTP-binding protein 162, 236 lithium 268 local circuit neurons 102 hallucinations 175 locomotion 140 haloperidol 32, 196,223, 307 locus ceruleus 91 heart 225 lordosis behaviour 143 heroin 203 Ltk cells 136 hippocampus, dentate gyrus 137 luteinizing hormone-releasing hormone histofiuorescence method 6 (LH-RH) 90 homovanillic acid 10 LY 270411 131 Huntington's chorea 26,36,127,170 lysergic acid diethylamide (LSD) 24 hydrogen peroxide 170 5-hydroxydopamine 64 magnesium block 305 6-hydroxydopamine 7,65,167,192,203, mania 206, 281 278 mazindol 257, 270 D,L-5-hydroxytryptophan 3 median eminence 90, 97 5-hydroxytryptophan 26 medium spiny neurons 300 3-hydroxytyramine 2 melanotroph cells 161 hyperiocomotion 277 membrane presentation 159 hypermotility 276 memory 276,309 hypodopaminergia 36 mesencephalon 265 hypothalamus 265 mesocortical projection 83 mesocorticolimbic pathway 176 iloperidone 196 metamphetamine 170, 279 imipramine 30, 207 methadone 14 immunogold labeling method 75,267 3-methoxytyramine 32 342 Subject Index I-methyl-4-phenyl-l,2,3,6- nucleus basalis of Meynert 79 tetrahydropyridine (MPTP) 7, 36, nucleus ruber 44 142,192,257 I-methyl-4-phenylpyridinium (MPP+) olanzapine 223,334 260 olfactory neurons 246 olfactory tubercle 6,77,137,264 Michaelis-Menten-equation 269 open field test 168 midbrain tegmentum 6 opiates 33, 169 mitochondria 100 opioid peptides 97 mitogen-activated protein 192 osmium tetroxide 64 mitogen-activated protein kinase oxidative stress 171 (MAPK) 163, 246, 322 oxytocin 91 mitogenesis 186 monoamine axons 100 pain 98 monoamine cortical systems 84 pallidum, ventral 79 monoamine oxidase (MAO) inhibitor para brachial pigmented nuclei 43 30 paranigral nucleus 43 monoamine oxidase B 8, 170, 279 parathyroid hormone 235 morphine 14 para ventricular nucleus 91 motivation 43 Parkinsonism, reserpin induced 4, 26 motor activity 276 Parkinsonism, postencephalitic 31 motor control 43 Parkinson's disease 104,142,159,170, motor function 98, 166 267,281,299 motor memory 310 - unilateral 10 motor regions 53 parvalbumin 87 MPP+ 8 pathways, nigrostriatal 44 multiple system atrophy 273 pathways, striatonigral 44 myoclonic jerking 139 pertussis toxin 133 phenoxybenzamine 32 nafadotride 193 phenylethanolamnie neocortex 137 N-methyltransferase (PNMT) 81 neostriatum 299,308 phosphatidylinositol 322 neurabin 1 241 phosphoinositide (PI) 145 neuromelanin 44 phospholipase A2 163,310 neuropeptide Y 73 phospholipase C (PLC) 238 neuropil 87 photoreceptor 95 neurosurgery, functional 9 pimozide 196,275 neurotensin 78,82,187,329 pipotiazine 196 neurotensin gene transcripts 199 pituitary (gland) 90, 171, 225 nicotinamide adenine dinucleotide pituitary hormones 98 phosphate (NADPH) 73 pituitary tumors 159, 172 nicotine 205 pituitary, anterior 6 nigrostriatal pathway 6, 176 plexiform layer 93 N-methyl-D-aspartate 240 PNMT antibodies 82 nociception 97 POU transcription factor 122 nomifensine 206,257,270 3-PPP 34 noradrenaline (NA) 8,209,223 pramipexole 210 noradrenaline transporter (NET) 258 premotor regions 53 norepinephrine (NE) fibers 64 prochlorperazine 196 norepinephrine (NE), see Noradrenaline progesterone 171 normethanephrine 32 progressive supranuclear palsy 273 northern analysis 265 projection system, striato-nigro-striatal nuclease protection assay 265 50 nucleus accumbens 6,50,65,68,79, projection, central striatum 49 136,187,264 projection, striatonigral 48 - shell 79 projections, corticostriatal 52 Subject Index 343 projections, corticothalamic 52 somatostatin 82 prolactin 171 somatostatin receptor 164 prolactinoma 172 spectrophotofluorimeter 24 proopiomelanocortin (POMC) 172 spinal cord 98 protein kinase A 136,239,322 spinophilin 241 protein phosphatase 1 (PP1) 241 spiny dendrites 72 projection, dorsolateral striatal 48 spiperone 223 pseudo-rabies-virus 86 stabilizers, dopaminergic 36 psychosis 173 stathmin 240 psychostimulants 201 stochastic resonance 103 psychotic reaction 13 stress 209 puncta adherentia 102 stress-activated protein (SAP) kinase
Load more

Recommended publications
  • Inhibition of 50-Khz Ultrasonic Vocalizations by Dopamine Receptor Subtype-Selective Agonists and Antagonists in Adult Rats
    Psychopharmacology (2013) 226:589–600 DOI 10.1007/s00213-012-2931-6 ORIGINAL INVESTIGATION Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats Tina Scardochio & Paul B. S. Clarke Received: 6 September 2012 /Accepted: 13 November 2012 /Published online: 29 November 2012 # Springer-Verlag Berlin Heidelberg 2012 Abstract calling. The D4 agonist and antagonist did not significantly Rationale Adult rats emit ultrasonic calls at around 22 and affect 50-kHz call rates. Twenty-two-kilohertz calls oc- 50 kHz, which are often elicited by aversive and rewarding curred infrequently under all drug conditions. stimuli, respectively. Dopamine (DA) plays a role in aspects Conclusion Following systemic drug administration, tonic of both reward and aversion. pharmacological activation of D1-like or D2-like DA recep- Objective The purpose of this study is to investigate the tors, either alone or in combination, does not appear suffi- effects of DA receptor subtype-selective agonists on 22- cient to induce 50-kHz calls. Dopaminergic transmission and 50-kHz call rates. through D1, D2, and D3 receptors appears necessary for Methods Ultrasonic calls were recorded in adult male rats spontaneous calling. that were initially screened with amphetamine to eliminate low 50-kHz callers. The remaining subjects were tested after Keywords Vocalization . Dopamine receptor . Reward . acute intraperitoneal or subcutaneous injection of the fol- Aversion . Agonist . Antagonist . Reinforcement . lowing DA receptor-selective agonists and antagonists: Behavior . D1 [D-1] . D2 [D-2] A68930 (D1-like agonist), quinpirole (D2-like agonist), PD 128907 (D3 agonist), PD 168077 (D4 agonist), SCH 39166 (D1-like antagonist), L-741,626 (D2 antagonist), Introduction NGB 2904 (D3 antagonist), and L-745,870 (D4 antagonist).
    [Show full text]
  • Sex Differences in Nicotine-Conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes
    East Tennessee State University Digital Commons @ East Tennessee State University Electronic Theses and Dissertations Student Works 8-2008 Sex Differences in Nicotine-Conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes. Ashley Brianna Sheppard East Tennessee State University Follow this and additional works at: https://dc.etsu.edu/etd Part of the Hormones, Hormone Substitutes, and Hormone Antagonists Commons Recommended Citation Sheppard, Ashley Brianna, "Sex Differences in Nicotine-Conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes." (2008). Electronic Theses and Dissertations. Paper 1978. https://dc.etsu.edu/etd/ 1978 This Thesis - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. Sex Differences in Nicotine-conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes A thesis presented to the faculty of the Department of Psychology East Tennessee State University In partial fulfillment of the requirements for the degree of Master of Arts in Psychology by Ashley Brianna Sheppard August 2008 Russell Brown, PhD., Chair Michael Woodruff, PhD., Committee member Otto Zinser,
    [Show full text]
  • Pharmacological Stimulation of Brain Dopamine D3 Receptors Induced
    ABSTRACT Pharmacological stimulation of brain dopamine D3 receptors induced ejaculation in anaesthetised rats # 163 Pierre Clément 1, Jacques Bernabé 1, Laurent Alexandre 1, François Giuliano 1,2 * 1PELVIPHARM Laboratories, Gif-sur-Yvette, France 2Raymond Poincaré Hospital, Neuro-Urology Unit, Garches, France * e-mail address: [email protected] ABSTRACT INTRODUCTION & OBJECTIVE RESULTS Introduction and Objective : We have previously found that intracerebroventricular (i.c.v.) Ejaculation consists in two distinct and successive phases i.e. emission and expulsion with the latter caused Figure 1 . Sample of EMG recording of the injection of the non selective dopamine D2/D3 receptors agonist by rhythmic contractions of pelvic floor striated muscles; the primary role being played by bulbospongiosus 7-OH-DPAT i.c.v. bulbospongiosus (BS) muscles obtained in quinelorane induced rhythmic (BS) muscles (Gerstenberg et al., 1990). (1 µg) anaesthetised rats after i.c.v. delivery of 7- contractions of bulbospongiosus 10 s (BS) muscles, which is key for OH-DPAT (1 µg). expelling semen out the urethra, in anaesthetised rats. In the present We have previously reported that the dopamine D2-like receptor agonist quinelorane delivered in cerebral A magnification of the tracing of BS-EMG is study we aimed at demonstrating ventricle was capable to elicit rhythmic BS muscles contractions in anaesthetised rats (Clement et al., 2006; displayed in the inset and allows to see the which of these dopamine receptor subtypes is involved in triggering BS EAU 2006, poster #164). In addition it has been shown that the preferential D3 receptor agonist 7-OH-DPAT V unitary events (i.e.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0052435 A1 Van Der Graaf Et Al
    US 20060052435A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0052435 A1 Van der Graaf et al. (43) Pub. Date: Mar. 9, 2006 (54) SELECTIVE DOPAMIN D3 RECEPTOR (86) PCT No.: PCT/GB02/05595 AGONSTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION (30) Foreign Application Priority Data (76) Inventors: Pieter Hadewijn Van der Graaf, Dec. 18, 2001 (GB) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - O1302199 County of Kent (GB); Christopher Peter Wayman, County of Kent (GB); Publication Classification Andrew Douglas Baxter, Bury St. Edmunds (GB); Andrew Simon Cook, (51) Int. Cl. County of Kent (GB); Stephen A6IK 31/405 (2006.01) Kwok-Fung Wong, Guilford, CT (US) (52) U.S. Cl. .............................................................. 514/419 Correspondence Address: (57) ABSTRACT PFIZER INC. PATENT DEPARTMENT, MS8260-1611 The use of a composition comprising a Selective dopamine EASTERN POINT ROAD D3 receptor agonist, wherein Said dopamine D3 receptor GROTON, CT 06340 (US) agonist is at least about 15-times more functionally Selective for a dopamine D3 receptor as compared with a dopamine (21) Appl. No.: 10/499,210 D2 receptor when measured using the same functional assay, in the preparation of a medicament for the treatment and/or (22) PCT Filed: Dec. 10, 2002 prevention of Sexual dysfunction. Patent Application Publication Mar. 9, 2006 Sheet 1 of 2 US 2006/0052435 A1 Figure 1 A Selective D3 agonist provides a significant therapeutic window between prosexual and dose-limitind side effects Apomorphine EHV VE - vomiterection D27.2nMD33.9nM E HV H - hypotension O3 0.56nM Log Free plasma O. 1.0 O 1OO 1OOO conc (nM) D3D24973M agonist E noH noV D2 adOnist D2 ag Conclusion D3 No effect D2 & D3 mediates erection D2 mediates vomiting/hypotension Patent Application Publication Mar.
    [Show full text]
  • Antipsychotic Drugs Influence Dopamine Neuron Terminals Via Action on D2‐Receptors and Vesicles
    Antipsychotic Drugs Influence Dopamine Neuron Terminals via Action on D2‐receptors and Vesicles Alex Klausing Honors Thesis in the Pharmaceutical Sciences Major College of Pharmacy The Ohio State University Advisor: Lane J. Wallace Spring 2013 Abstract Dopamine D2 antagonist antipsychotic drugs share the effects of increasing dopamine synthesis, dopamine neuron firing rate, and dopamine and DOPAC levels. These antagonists all raise extracellular dopamine to approximately 163% of control and DOPAC levels to approximately 200% of control without changing tissue level of dopamine. Variability in striatal tissue DOPAC level (190 – 350% of control) and rates of dopamine synthesis (190‐378% of control) reported after administration of various antipsychotic drugs gives evidence that these parameters are influenced by factors besides the antagonism of the D2 receptor. We used a computational model of dopaminergic terminals in the striatum to determine what parameters other than D2 receptors might be targets for the drugs. Simulation model results suggest that D2 receptor antagonism results in a slight increase in rate of dopamine exocytosis accompanied by a small increase in rate of dopamine synthesis needed to maintain the increase in rate of exocytosis and a small increase in rate of dopamine synthesis specifically dedicated to DOPAC secretion. Simulation model results also suggest that variable increases in levels of tissue DOPAC result from increases in passive diffusion of dopamine out from vesicles coupled with an increase in rate of dopamine synthesis required to maintain tissue levels of dopamine. Biochemical data reported in the literature suggests changes in passive diffusion depend on the ability of the antipsychotic drug to diffuse into and alkalinize vesicles.
    [Show full text]
  • Parkinson's Disease Quality Measurement Set Update
    Parkinson’s Disease Quality Measurement Set Update Approved by the Parkinson’s Disease Update Quality Measurement Development Work Group on September 3, 2015, by the AAN Quality and Safety Subcommittee on September 23, 2015; by the AAN Practice Committee on October 19, 2015; and by the AANI Board of Directors on November 5, 2015. ©2015. American Academy of Neurology. All Rights Reserved. 1 CPT Copyright 2004-2013 American Medical Association. Disclaimer Performance Measures (Measures) and related data specifications developed by the American Academy of Neurology (AAN) are intended to facilitate quality improvement activities by providers. AAN Measures: 1) are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications; 2) are not continually updated and may not reflect the most recent information; and 3) are subject to review and may be revised or rescinded at any time by the AAN. The measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by health care providers in connection with their practices); they must not be altered without prior written approval from the AAN. Commercial use is defined as the sale, license, or distribution of the measures for commercial gain, or incorporation of the measures into a product or service that is sold, licensed, or distributed for commercial gain. Commercial uses of the measures require a license agreement between the user and the AAN. Neither the AAN nor its members are responsible for any use of the measures. AAN Measures and related data specifications do not mandate any particular course of medical care and are not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients.
    [Show full text]
  • Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
    biomolecules Review Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders Béla Kiss 1, István Laszlovszky 2, Balázs Krámos 3, András Visegrády 1, Amrita Bobok 1, György Lévay 1, Balázs Lendvai 1 and Viktor Román 1,* 1 Pharmacological and Drug Safety Research, Gedeon Richter Plc., 1103 Budapest, Hungary; [email protected] (B.K.); [email protected] (A.V.); [email protected] (A.B.); [email protected] (G.L.); [email protected] (B.L.) 2 Medical Division, Gedeon Richter Plc., 1103 Budapest, Hungary; [email protected] 3 Spectroscopic Research Department, Gedeon Richter Plc., 1103 Budapest, Hungary; [email protected] * Correspondence: [email protected]; Tel.: +36-1-432-6131; Fax: +36-1-889-8400 Abstract: Dopamine (DA), as one of the major neurotransmitters in the central nervous system (CNS) and periphery, exerts its actions through five types of receptors which belong to two major subfamilies such as D1-like (i.e., D1 and D5 receptors) and D2-like (i.e., D2, D3 and D4) receptors. Dopamine D3 receptor (D3R) was cloned 30 years ago, and its distribution in the CNS and in the periphery, molecular structure, cellular signaling mechanisms have been largely explored. Involvement of D3Rs has been recognized in several CNS functions such as movement control, cognition, learning, reward, emotional regulation and social behavior. D3Rs have become a promising target of drug research and great efforts have been made to obtain high affinity ligands (selective agonists, partial agonists and antagonists) in order to elucidate D3R functions. There has been a strong drive behind the efforts to find drug-like compounds with high affinity and selectivity and various functionality for D3Rs in the hope that they would have potential treatment options in CNS diseases such as schizophrenia, drug abuse, Parkinson’s disease, depression, and restless leg syndrome.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • 037P Neuroprotective Effect of Glucagon-Like Peptide-1 Receptor
    Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol6Issue4abst037P.pdf 037P Neuroprotective effect of glucagon-like peptide-1 receptor stimulation in rat model of Parkinson’s Disease is blocked by both Exendin-9-39 and Nafadotride Alexander Harkavyi1, Amjad Abuirmeileh1, Rebecca Lever1, Ann Kingsbury2, Chris Biggs3, Peter Whitton1 1The School of Pharmacy, University of London, London, UK, 2University College London, London, UK, 3University of Westminster, London, UK The glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (EX-4) has been found to be neurotrophic and neuroprotective in vitro (Perry et al., 2002) leading to the suggestion that stimulation of GLP-1 receptors could have therapeutic value in neurodegenerative disorders such as Parkinson’s disease (PD). Recently, protective effects of exendin-4 were demonstrated in two in vivo rodent models of PD (Harkavyi et al., 2008) and it has also been shown to promote neurogenesis in the rat subventricular zone (SVZ) (Bertilsson et al., 2008). Here we demonstrate that neuro-protective/trophic effects of exendin-4 in a 6-OHDA model of PD are mediated via both, GLP-1R and dopamine D3-receptors. Male Wistar rats (250-280g; n = 6 per group) were anaesthetised with isoflurane and 8µg of 6- OHDA was stereotaxically injected into the medial forebrain bundle. 7 days later rats were administered EX-4 (0.5µg kg-1 in saline) together with EX-9-39 (GLP-1R antagonist 1µg kg-1) or Nafadotride (D3 antagonist 1µg kg-1) twice daily. Another week later rats were challenged with 0.5 mg kg-1 of apomorphine to evaluate contralateral circling behaviour and were then implanted with microdialysis probes and the following day perfused with artificial cerebrospinal fluid at a rate of 1µl min-1.
    [Show full text]
  • Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms
    PROTEOSTASIS OF GLIAL INTERMEDIATE FILAMENTS: DISEASE MODELS, TOOLS, AND MECHANISMS Rachel Anne Battaglia A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Cell Biology and Physiology in the School of Medicine. Chapel Hill 2021 Approved by: Natasha T. Snider Carol Otey Keith Burridge Douglas Cyr Mohanish Deshmukh Damaris Lorenzo i © 2021 Rachel Anne Battaglia ALL RIGHTS RESERVED ii ABSTRACT Rachel Anne Battaglia: Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms (Under the direction of Natasha T. Snider) Astrocytes are a major glial cell type that is crucial for the health and maintenance of the Central Nervous System (CNS). They fulfill diverse functions, including synapse formation, neurogenesis, ion homeostasis, and blood brain barrier formation. Intermediate filaments (IFs) are components of the astrocyte cytoskeleton that support many of these functions in healthy individuals. However, upon cellular stress or genetic mutations, IF proteins are prone to accumulation and aggregation. These processes are thought to contribute to disease pathogenesis of different tissue-specific disorders, but therapeutic targeting of IFs is hindered by a lack of pharmacological tools to modulate their assembly and disassembly states. Moreover, the mechanisms that govern the formation and dissolution of IF aggregates are poorly defined. In this dissertation, I investigate IF aggregates called Rosenthal fibers (RFs), which form in astrocytes of patients with two pediatric neurodegenerative diseases, Alexander disease (AxD) and Giant Axonal Neuropathy (GAN). My aim was to gain a better understanding of the mechanisms of how astrocyte IF protein aggregates form and interrogate the role of post- translational modifications (PTMs) in this process.
    [Show full text]
  • PR2'2005.Vp:Corelventura
    Pharmacological Reports Copyright © 2005 2005, 57, 161169 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Central effects of nafadotride, a dopamine D3 receptor antagonist, in rats. Comparison with haloperidol and clozapine* Grzegorz Kuballa1, Przemys³aw Nowak1, £ukasz Labus1, Aleksandra Bortel1, Joanna D¹browska1, Marek Swoboda1, Adam Kwieciñski1, Richard M. Kostrzewa2, Ryszard Brus1 Department of Pharmacology, Medical University of Silesia, Jordana 38, PL 41-808 Zabrze, Poland Department of Pharmacology, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA Correspondence: Ryszard Brus, e-mail: [email protected] Abstract: The aim of this study was to examine behavioral and biochemical effects of nafadotride, the new dopamine D! receptor antagonist, and to compare it with haloperidol (dopamine D receptor antagonist) and clozapine (predominate dopamine D" receptor antagonist). Each drug was injected to adult male Wistar rats intraperitoneally, each at a single dose and for 14 consecutive days. Thirty minutes after single or last injection of the examined drugs, the following behavioral parameters were recorded: yawning, oral activity, locomotion, exploratory activity, catalepsy and coordination ability. By HPLC/ED methods, we determined the effects of the examined antagonists on the levels of biogenic amines in striatum and hippocampus: dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 3-methoxytyramine (3-MT), 5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid (5-HIAA) and noradrenaline (NA). Additionally, DA and 5-HT synthesis rate was determined in striatum and 5-HT in hippocampus. The results of the study indicate that nafadotride, the dopamine D! receptor antagonist, has a behavioral and biochemical profile of action different from that of haloperidol but partially similar to that of clozapine.
    [Show full text]
  • Dopamine Receptor D3 T Cells Via + Homing of Naive CD8 Dopamine
    Dopamine Selectively Induces Migration and Homing of Naive CD8 + T Cells via Dopamine Receptor D3 This information is current as Yoshiko Watanabe, Takashi Nakayama, Daisuke Nagakubo, of September 29, 2021. Kunio Hieshima, Zhe Jin, Fuminori Katou, Kenji Hashimoto and Osamu Yoshie J Immunol 2006; 176:848-856; ; doi: 10.4049/jimmunol.176.2.848 http://www.jimmunol.org/content/176/2/848 Downloaded from References This article cites 44 articles, 12 of which you can access for free at: http://www.jimmunol.org/content/176/2/848.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Dopamine Selectively Induces Migration and Homing of Naive CD8؉ T Cells via Dopamine Receptor D31 Yoshiko Watanabe,*† Takashi Nakayama,* Daisuke Nagakubo,* Kunio Hieshima,* Zhe Jin,* Fuminori Katou,† Kenji Hashimoto,† and Osamu Yoshie2* The nervous systems affect immune functions by releasing neurohormones and neurotransmitters.
    [Show full text]